ATE506957T1 - Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen - Google Patents

Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen

Info

Publication number
ATE506957T1
ATE506957T1 AT07742308T AT07742308T ATE506957T1 AT E506957 T1 ATE506957 T1 AT E506957T1 AT 07742308 T AT07742308 T AT 07742308T AT 07742308 T AT07742308 T AT 07742308T AT E506957 T1 ATE506957 T1 AT E506957T1
Authority
AT
Austria
Prior art keywords
protein
prophylactic
therapeutic agent
neurodegenerative diseases
acid sequence
Prior art date
Application number
AT07742308T
Other languages
English (en)
Inventor
Hitoshi Okazawa
Original Assignee
Nat Univ Corp Tokyo Med & Dent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Corp Tokyo Med & Dent filed Critical Nat Univ Corp Tokyo Med & Dent
Application granted granted Critical
Publication of ATE506957T1 publication Critical patent/ATE506957T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07742308T 2006-06-01 2007-04-24 Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen ATE506957T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006154059A JP4982739B2 (ja) 2006-06-01 2006-06-01 ポリグルタミン病の予防・治療剤
PCT/JP2007/058873 WO2007138810A1 (ja) 2006-06-01 2007-04-24 神経変性疾患の予防・治療剤

Publications (1)

Publication Number Publication Date
ATE506957T1 true ATE506957T1 (de) 2011-05-15

Family

ID=38778331

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07742308T ATE506957T1 (de) 2006-06-01 2007-04-24 Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen

Country Status (6)

Country Link
US (1) US7833975B2 (de)
EP (1) EP2039367B1 (de)
JP (1) JP4982739B2 (de)
AT (1) ATE506957T1 (de)
DE (1) DE602007014210D1 (de)
WO (1) WO2007138810A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110017371A (ko) 2008-04-30 2011-02-21 가부시키가이샤 제노믹스 생체내 기능적 세포의 고효율 채취법
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
KR102113809B1 (ko) 2011-04-26 2020-05-21 가부시키가이샤 스템림 조직 재생을 유도하기 위한 펩티드 및 그의 이용
CA2889275C (en) 2012-10-25 2021-06-15 Katsuto Tamai Novel method for treating cardiac infarction using hmgb1 fragment
ES2673861T3 (es) 2012-10-25 2018-06-26 Genomix Co., Ltd. Método novedoso para tratar el daño a la médula espinal utilizando el fragmento de hmgb1
US10989719B2 (en) 2013-10-11 2021-04-27 National University Corporation Tokyo Medical And Dental University Methods for treating spinocerebellar ataxia type I using RPA1
EP3502248B1 (de) * 2016-08-09 2024-05-29 National University Corporation Tokyo Medical and Dental University Antikörper gegen hmgb1 und zusammensetzung damit zur behandlung oder vorbeugung von morbus alzheimer
JP6984815B2 (ja) * 2016-09-12 2021-12-22 国立大学法人 東京医科歯科大学 神経変性疾患タンパク質の異常凝集を伴って発症する神経疾患に対する予防又は治療剤、及び上記予防又は治療剤のスクリーニング方法
PL3556378T3 (pl) 2017-01-27 2025-06-09 StemRIM Inc. Środek do leczenia kardiomiopatii, starego zawału mięśnia sercowego i przewlekłej niewydolności serca
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
CN118460462A (zh) 2017-12-01 2024-08-09 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
WO2021242180A1 (en) * 2020-04-22 2021-12-02 Chulalongkorn University A composition and a method of rejuvenating dna and preventing dna damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4255101B2 (ja) 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
EP1668035A2 (de) * 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoklonale antikörper gegen hmgb1
US7618793B2 (en) * 2004-10-20 2009-11-17 The Regents Of The University Of Washington Identifying agents for decreasing cellular toxicity associated with huntingin polypeptide

Also Published As

Publication number Publication date
US7833975B2 (en) 2010-11-16
WO2007138810A1 (ja) 2007-12-06
EP2039367A1 (de) 2009-03-25
US20090280488A1 (en) 2009-11-12
EP2039367A4 (de) 2009-12-30
EP2039367B1 (de) 2011-04-27
JP2007320919A (ja) 2007-12-13
JP4982739B2 (ja) 2012-07-25
DE602007014210D1 (de) 2011-06-09

Similar Documents

Publication Publication Date Title
DE602007014210D1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
ATE483027T1 (de) Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
SE0301010D0 (sv) Novel compounds
MX2009002816A (es) Proteinas de fusion de albumina.
WO2009004315A8 (en) Isolated peptides and uses thereof
MX2008001865A (es) Proteinas de fusion de albumina.
SE0301009D0 (sv) Novel compounds
IN2012DN03368A (de)
EP2455462A3 (de) Lipasevarianten zur pharmazeutischen Verwendung
SG170116A1 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007141274A3 (en) Human binding molecules having killing activity against staphylococci and uses thereof
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
ATE417595T1 (de) Keratin-bindende polypeptide
MX2009006617A (es) Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
WO2008061208A3 (en) Arylsulfonamide compounds
MX2008009493A (es) Peptido novedoso y uso del mismo.
EP1801206A4 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
WO2008051326A3 (en) Identification of contactins and l1- cams as ligands for the amyloid precursor protein
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2007132292A3 (en) Therapy for alzheimer's disease
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties